The pressure is on for those earnings to support the market's current valuations, after weeks of choppy trading.» Read More
LONDON, April 9- The World Health Organisation wants a "concerted effort" to drive down the cost of new hepatitis C drugs that offer a cure for the liver-destroying virus but are unaffordable for most infected people worldwide.
NEW YORK— Wall Street's cool kids have been booted from the lunchroom. Twitter is down 35 percent since early March and Amazon.com has slid 19 percent. Gilead Sciences is down 16 percent and Vertex Pharmaceuticals has fallen 23 percent.
*Amazon.com, Yahoo shares jump; investors buy Internet' bargains'. *Alcoa starts earnings season; shares up after results. The day's biggest gainers included Amazon.com Inc, up 2.9 percent at $327.07; Yahoo Inc, up 2.3 percent at $33.83; and LinkedIn Corp, up 5.9 percent at $169.10.
Some of Tuesday's midday movers:
*Amazon.com, Yahoo shares up 3 pct on Internet rebound. *Earnings get under way; Alcoa to report after bell. The day's biggest gainers included Amazon.com Inc up 2.3 percent at $324.99, Yahoo!
NEW YORK— Stocks are closing higher as the market stabilizes after a three-day slump. Bed Bath& Beyond reports after the market closes Wednesday and JPMorgan Chase releases its results on Friday.
*Working on more tiered pricing after deal with Egypt. LONDON, April 8- Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations.
Amgen Inc. rose$. 10 or. 1 percent, to $118.92. Biogen Idec fell $4.31 or 1.5 percent, to $289.88. Celgene Corp. fell $1.32 or. 9 percent, to $137.84.
*Eli Lilly ordered to pay $3 bln in damages in Actos case. *Alcoa earnings due after the close.
Despite the recent meltdown in biotech, there are still areas of opportunity within the sector, Citi's Yaron Werber says.
Amgen Inc. fell$. 29 or. 2 percent, to $118.82. Biogen Idec rose $5.92 or 2.1 percent, to $294.19. Celgene Corp. rose $1.78 or 1.3 percent, to $139.16.
OMAHA, Neb.— Investors who buy stocks with TD Ameritrade remained heavily invested and active in March. TD Ameritrade said Monday that its Investor Movement index increased to another all-time high of 5.87 in March from February's 5.74. Technology and health care stocks were popular with TD Ameritrade investors, especially Gilead Sciences and Facebook.
Amgen Inc. fell$. 47 or. 4 percent, to $118.64. Biogen Idec rose $4.41 or 1.5 percent, to $292.68. Celgene Corp. rose$. 89 or. 6 percent, to $138.27.
*MannKind stumbles; FDA extends drug review date. However, other names such as Facebook Inc, up 1 percent to $57.33 and Gilead Sciences Inc, up 0.8 percent at $72.76, were able to reverse initial declines.
NEW YORK, April 7- U.S. stocks opened lower on Monday, with the S&P 500 on track for its third straight decline, as weakness in some of the market's recent high-flying names continued. Yahoo Inc fell 2 percent to $33.58, Biogen lost 2.2 percent to $282 and Gilead Sciences Inc fell 1.3 percent to $71.04.
*E* Trade and Netflix weigh on S&P 500 and Nasdaq. NEW YORK, April 4- Momentum shares like Netflix and TripAdvisor sold off sharply for a second straight day on Friday, giving the Nasdaq its worst day since February and leaving investors anxious about how much further they may fall.
*E* Trade and Netflix weigh on S&P 500 and Nasdaq. NEW YORK, April 4- U.S. stocks fell sharply on Friday as momentum shares like Netflix and TripAdvisor sold off for a second straight session, putting the Nasdaq on track for its second-worst day of the year.
*E* Trade and Netflix weigh on S&P 500 and Nasdaq. NEW YORK, April 4- The Nasdaq tumbled more than 2 percent on Friday as momentum stocks like Netflix and TripAdvisor sold off for a second straight session.
*E* Trade and Netflix weigh on the S&P 500 and the Nasdaq. NEW YORK, April 4- The Nasdaq tumbled more than 2 percent on Friday, led by another selloff in momentum stocks like Netflix and TripAdvisor, as investors ignored relatively strong March jobs data. Biogen Idec Inc fell 3.6 percent to $291.
CEO pay jumped a whopping 13% in 2013 to break the $10 million barrier with the median compensation hitting $10.5 million.